Table 3.
Risk of selected neurological and autoimmune diseases in vaccinated versus unvaccinated cohort and in subcohorts vaccinated in early and late phases of H1N1 vaccination campaign in Stockholm county, Sweden
| Diseases and vaccination status | Hazard ratio (95% CI)* | |
|---|---|---|
| Model 1 | Model 2 | |
| Neurological diseases | ||
| Bell’s palsy: | ||
| All vaccinated | 1.35 (1.14 to 1.59) | 1.25 (1.06 to 1.48) |
| ≤45 days | 1.49 (1.23 to 1.81) | 1.34 (1.11 to 1.64) |
| >45 days | 1.19 (0.97 to 1.47) | 1.16 (0.94 to 1.43) |
| Guillain-Barré syndrome: | ||
| All vaccinated | 1.27 (0.79 to 2.06) | 1.07 (0.66 to 1.74) |
| ≤45 days | 1.40 (0.81 to 2.42) | 1.08 (0.62 to 1.87) |
| >45 days | 1.13 (0.61 to 2.09) | 1.07 (0.58 to 1.99) |
| Multiple sclerosis: | ||
| All vaccinated | 0.99 (0.73 to 1.35) | 0.93 (0.68 to 1.26) |
| ≤45 days | 1.17 (0.82 to 1.66) | 1.04 (0.72 to 1.48) |
| >45 days | 0.81 (0.54 to 1.21) | 0.80 (0.54 to 1.20) |
| Anaesthesia or hypoaesthesia: | ||
| All vaccinated | 1.18 (0.87 to 1.61) | 1.05 (0.77 to 1.43) |
| ≤45 days | 1.50 (1.06 to 2.12) | 1.23 (0.86 to 1.74) |
| >45 days | 0.86 (0.57 to 1.30) | 0.84 (0.56 to 1.27) |
| Paraesthesia: | ||
| All vaccinated | 1.20 (1.08 to 1.33) | 1.11 (1.00 to 1.23) |
| ≤45 days | 1.43 (1.27 to 1.61) | 1.25 (1.10 to 1.41) |
| >45 days | 0.96 (0.83 to 1.10) | 0.94 (0.82 to 1.09) |
| Polyneuropathy: | ||
| All vaccinated | 1.33 (1.11 to 1.59) | 1.11 (0.92 to 1.32) |
| ≤45 days | 1.40 (1.15 to 1.71) | 1.09 (0.89 to 1.33) |
| >45 days | 1.22 (0.97 to 1.53) | 1.14 (0.90 to 1.44) |
| Narcolepsy: | ||
| All vaccinated | 1.45 (0.56 to 3.75) | 1.25 (0.47 to 3.30) |
| ≤45 days | 1.82 (0.63 to 5.21) | 1.38 (0.46 to 4.17) |
| >45 days | 1.10 (0.34 to 3.59) | 1.12 (0.34 to 3.66) |
| Narcolepsy (aged ≤20 years): | ||
| All vaccinated | 1.54 (0.30 to 7.89) | 1.54 (0.30 to 8.01) |
| ≤45 days | 0.67 (0.06 to 7.70) | 0.58 (0.05 to 6.69) |
| >45 days | 2.06 (0.38 to 11.0) | 2.21 (0.41 to 11.8) |
| Autoimmune diseases | ||
| Rheumatoid arthritis: | ||
| All vaccinated | 1.03 (0.89 to 1.19) | 0.94 (0.81 to 1.09) |
| ≤45 days | 1.17 (0.99 to 1.38) | 1.01 (0.86 to 1.20) |
| >45 days | 0.86 (0.71 to 1.04) | 0.84 (0.69 to 1.02) |
| Inflammatory bowel disease: | ||
| All vaccinated | 1.22 (1.04 to 1.42) | 1.13 (0.97 to 1.32) |
| ≤45 days | 1.43 (1.20 to 1.71) | 1.25 (1.04 to 1.50) |
| >45 days | 1.01 (0.83 to 1.23) | 1.00 (0.82 to 1.22) |
| Type 1 diabetes†: | ||
| All vaccinated | 1.03 (0.70 to 1.53) | 0.99 (0.67 to 1.47) |
| ≤45 days | 1.21 (0.77 to 1.89) | 1.13 (0.72 to 1.78) |
| >45 days | 0.91 (0.59 to 1.41) | 0.88 (0.57 to 1.38) |
Both models were adjusted for age, sex, and socioeconomic status. Model 2 was further adjusted for healthcare consumption (number of hospital admissions and visits to specialist care one year before pandemic period).
*Cox’s regression analyses.
†Population born 1990 or later.